ClinicalTrials.gg
RecruitingNCT06547489GATE-251Updated Aug 3, 2026

Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

A Phase 2 interventional study of Zelquistinel in Major Depressive Disorder, sponsored by Syndeio Biosciences, Inc. Recruiting at 34 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Syndeio Biosciences, Inc · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Planned enrollment
414th of 1,323
164 · median 70
Started
2025
with 69 others
Phase 2
271 of 1,500
45 open now
Primary completion
2027-09
later than 127 of 258 live
Registered
1,340th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 414th largest by planned enrollment of the 1,323 interventional ones that give a count, is one of 70 that started in 2025, is one of 271 in phase 2, reaches primary completion later than 127 of the 258 other live ones, and was the 1,340th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are:

Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no zelquistinel)?

What medical problems are observed in participants who take zelquistinel?

Participants will take one tablet of zelquistinel or placebo every week for 6 weeks. Participants will visit the clinic every week of the 6 week period to have the severity of their depression evaluated.

Read the detailed description

This is a Phase 2 multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed dose clinical trial designed to evaluate the safety and efficacy of zelquistinel versus placebo in subjects with symptoms of major depressive disorder. Each subject will participate in this study up to 98 days: up to 28 days for screening, 42 days for double-blind treatment, and a 4-week follow-up period. Subjects will return to the clinic one time each week to have the severity of their depression assessed using the Hamilton depression rating scale-17. Adverse events that occurred since the last study visit will be recorded.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • zelquistinel
  • GATE-251
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each subject must meet all of the following inclusion criteria to be eligible to participate in the study:

  1. Male or female subjects.
  2. Aged 18 to 64 years, inclusive.
  3. Subject has a diagnosis of major depressive disorder (MDD), single or recurrent episode, defined by the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition (); if single episode, the duration must be ≥8 weeks and ≤24 months. The diagnosis of MDD will be made by a site rater and supported by the Structured Clinical Interview for DSM-5 - Clinical Trials version (SCID-5-CT) and confirmed by remote, independent raters from the Massachusetts General Hospital Clinical Trials Network and Institute with a State versus trait, Assessability, Face validity, Ecological validity, and Rule of three Ps (pervasive, persistent, and pathological) (SAFER) interview:

    1. The current depressive episode is ≥8 weeks and ≤24 months in duration prior to the Screening Visit (V1);
    2. Have an appropriate severity of illness of at least moderately ill corresponding to a CGI-S score of ≥4 at the Screening and Baseline Visits (V1 and V2, respectively); and
    3. Importantly, have a sufficient history and/or independent report verifying that the current depressive episode is causing distress or impairment in functioning.
  4. Subject has a Hamilton Depression Rating Scale-17 (HDRS-17) using the Structured Interview Guide for the Hamilton Rating Scale for Depression (SIGH-D) total score of ≥18 at the Screening Visit (V1) and Baseline Visit (V2) with no more than a 25% change from the Screening Visit (V1) to the Baseline Visit (V2).
  5. (Inclusion 5 removed in protocol amendment 4)
  6. (Inclusion 6 removed in protocol amendment 4)
  7. Female subjects must meet 1 of the following:

    1. Surgically sterile or at least 2 years menopausal (ie, is defined as a woman with the absence of menses for at least 12 consecutive months). Menopausal status is to be confirmed by assessing the follicle stimulating hormone level at Screening Visit (V1), or,
    2. If a woman of child bearing potential, subject must use an acceptable method of from date of Screening to the last evaluation at Day 71. Must have a documented negative point of care urine pregnancy test within 24 hours prior to first dosing.
  8. Male subjects, including those who are surgically sterile, must use a medically acceptable form of contraception from the time of randomization until the last evaluation at Day 71. Male subjects are strongly advised to inform female partners of the need for them to use highly effective birth control during this time period.
  9. Subject must be medically stable by physical examination, medical history, vital signs, laboratory evaluations, and 12-lead performed at the Screening Visit (V1) and Baseline (V2). If abnormalities are found, the subject may be included if the Investigator, contract research organization (CRO) and sponsor medical monitors judge the abnormalities to be not clinically significant.
  10. Ability to understand the nature and requirements of the study and is willing to comply with the study restrictions and agree to return for the required assessments.
  11. Provides written to participate in the trial.
  12. Is able to communicate with site personnel, able to complete patient-reported outcome measures and in the opinion of the Investigator, can be reliably rated on assessment scales

Exclusion criteria

Exclusion Criteria:

Any subject who meets any of the following criteria will be excluded from study participation:

  1. Evidence of treatment-resistant MDD, defined by having an inadequate response (≤25%) to 2 or more different medications approved for the treatment of MDD at an adequate dose (per locally approved label) for an adequate duration during the current episode using the Massachusetts General Hospital Antidepressant Treatment Rating Questionnaire (ATRQ).
  2. Current diagnosis of bipolar (or related disorders), antisocial personality disorder, obsessive compulsive disorder, borderline personality disorder, post-traumatic stress disorder, panic disorder, or attention-deficit/hyperactivity disorder. Subjects not meeting full DSM 5 criteria for borderline personality disorder but exhibiting recurrent suicidal gestures, threats, or self-mutilating behaviors should also be excluded.
  3. Subject has a current or prior DSM-5 diagnosis of a psychotic disorder, or MDD with psychotic features.
  4. Current concomitant treatment with Food and Drug Administration (FDA)-approved antidepressants, antipsychotics, mood stabilizers, sedatives, or stimulants. Current or past treatment with esketamine, ketamine, or psychedelics is prohibited. Subject must have current concomitant treatment discontinued at least 14 days prior to the Baseline Visit (V2). Subjects may continue anxiolytic agents, except for drugs that are also used to treat depression, or benzodiazepines, or sleep aids [see Section 5.5.1 for a nonexhaustive list] (except trazodone) so long as they have been on a stable dose for at least 3 months and do not intend to change dose during double-blind treatment period (Day 1, Week 1 through end of Week 6 [Day 43]). Subjects who use cannabis or cannabis-derived molecules, including tetrahydrocannabinol (THC), whether natural or chemically-synthesized, hemp seed oil, or cannabidiol (CBD) products (eg, gummies), must be discontinued for at least 14 days prior to the Baseline Visit (V2).
  5. Treatment with any experimental antidepressant agent or treatment with a psychedelic agent in an FDA-approved clinical study within the past 12 months.
  6. History of electroconvulsive therapy, vagus nerve stimulation, deep brain stimulation, or repetitive transcranial magnetic stimulation within the past 5 years or has had a failure of response to electroconvulsive therapy at any time.
  7. Subject has renal dysfunction as assessed by the estimated \<70 mL/min using the Chronic Kidney Disease Epidemiology Collaboration - creatinine (CKD-EPI creatinine) methodology.
  8. Subject has liver protein and enzyme (alkaline phosphatase, , aspartate aminotransferase, gamma-glutamyl transferase, total , lactate dehydrogenase test result >1.5 times the (subjects with a diagnosis of Gilbert's Syndrome may be eligible if no liver function or enzyme test results other than total bilirubin are >1.5 times upper limit of normal).
  9. Subject has resting pulse rate (supine) \<50 or >100 bpm at the Screening Visit (V1) or predose Baseline (V2).
  10. Subject has resting diastolic blood pressure \<50 mmHg at the Screening Visit (V1) or predose Baseline (V2).
  11. Subject has cardiac PR interval >250 msec at the Screening Visit (V1) or predose Baseline (V2), or or QTcB interval >450 msec in males or >470 msec in females, or QRS interval >120 msec.
  12. Evidence of alcohol abuse (>4 units of alcohol on most days; 1 unit=½ pint of beer, 1 glass of wine, or 1 ounce of hard liquor/spirits) or a positive saliva alcohol screen at Screening (V1) and predose at the Baseline Visit (V2). Alcohol consumption should be avoided for at least 24 hours prior to Baseline Visit (V2). Note: Subject may not be rescreened.
  13. Abuse of illicit substances, including psychedelic mushrooms by DSM-5 definition of substance use disorder within the 12 months prior to the Screening Visit (V1). Positive urine test for any drug of abuse is exclusionary.
  14. Positive urine test for any drug of abuse (except cannabis or cannabis-derived molecules such as THC whether natural or chemically-synthesized [see exclusion criterion 4]). Prescribed barbiturates may be continued so long as subjects have been on a stable dose for at least 3 months and may not change dose during the double-blind treatment period. Subjects may not be rescreened after failing a drug screen for a drug of abuse.
  15. infection, COVID-19 infection, or active or C, syphilis, or other ongoing infectious disease at the Screening Visit (V1).
  16. Has laboratory evidence of hypothyroidism at Screening (V1) as measured by thyroid stimulating hormone (TSH) and reflex free thyroxine (T4). If TSH is abnormal and reflex T4 is normal, the subject may be included.
  17. Has current unstable diabetes or glycosylated () >7% at Screening (V1).
  18. Currently pregnant, planning to become pregnant during the course of the study, or nursing.
  19. Currently working a night shift or may be required to work night shift during the course of this study, from Screening through completion of final polysomnography.
  20. in the last 5 years, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
  21. Subject has received new onset psychotherapy or had a change in the intensity of psychotherapy within 8-weeks prior to the Screening Visit (V1).
  22. Currently taking prohibited prescription or over-the-counter medications including herbal therapies (eg, echinacea, ginseng, ginko, elderberry, turmeric, ginger, valerian, chamomile, or St John's wort) and THC or cannabis-containing products [see exclusion criterion 4], which may interfere with the required study psychiatric assessments.
  23. History of allergy or sensitivity, or intolerance to zelquistinel, NMDAR ligands including ketamine, dextromethorphan, memantine, methadone, dextropropoxyphene, or ketobemidone.
  24. Treatment with any other study drugs not used to treat depression within 90 days of screening in this study.
  25. Previously participated in this study or currently enrolled in any other clinical study.
  26. of >35 kg/m2 at the Screening Visit (V1).
  27. Subject is an employee of Worldwide Clinical Trials (hereafter referred to as Worldwide), the Investigator or study site with direct involvement in the study or other studies under the direction of that Investigator or study site, as well as a family member of an employee or of the Investigator, or an employee of Gate Neurosciences, Inc., or a family member of an employee.
  28. In the opinion of the Investigator,

    1. The subject has a significant risk for suicidal behavior during the course of participation in the study, or
    2. At the Screening Visit (V1) (the subject scores "Yes" on Items 4 or 5 in the Suicidal Ideation section of the Columbia Suicide Severity Rating Scale (C-SSRS) with reference to a 6-month period prior to Screening Visit (V1), or
    3. At Screening (V1) the subject has had 1 or more suicidal attempts with reference to a 2-year period prior to Screening Visit (V1), or
    4. The subject is considered to be an imminent danger to themself or others, or
    5. At the Baseline Visit (V2) (the subject scores "Yes" on Items 4 or 5 in the Suicidal Ideation section of the C-SSRS
  29. The subject is judged by the Investigator or CRO and Sponsor medical monitors to be inappropriate for the study for any reason.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
164 participants (estimated)

Study arms

  • Experimental
    zelquistinel (GATE-251)

    zelquistinel (GATE-251) will be administered as a single 10 mg oral tablet one time each week for 6 weeks.

    Drug: Zelquistinel

  • Placebo comparator
    Placebo

    Placebo tablet identical in appearance to the experimental treatment tablet, administered as as a single oral tablet one time each week for 6 weeks.

    Drug: Zelquistinel

Interventions

  • Zelquistinel is a positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor

    Also known as: GATE-251

06

What researchers measure

Primary outcomes

  1. Change in the Hamilton Depression Rating Scale-17 (HDRS-17) score compared to placebo

    HDRS-17 is used to assess the severity of depression. The range of scores for the HDRS-17 is 0 - 52 with lower scores indicating a better outcome

    Time frame: Change in score from predose baseline to end of week 6

Secondary outcomes

  1. Change in the Clinical Global Impressions - Severity (CGI-S) score compared to placebo

    The CGI-S is a 7-level rating scale used by a clinician to gauge depression severity. The range of scores is 0-7 with lower scores indicating a better outcome.

    Time frame: Change in score from predose baseline to end of week 6

07

Study locations

21 of 34 sites recruiting
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
    Recruiting
  • University of Alabama at Birmingham-Huntsville
    Huntsville, Alabama 35801, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Wr-Pri, Llc
    Encino, California 91316, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Irvine Clinical Research
    Irvine, California 92614, United States
    Recruiting
  • CalNeuro Research Group
    Los Angeles, California 90025, United States
    Recruiting
  • Pacific Clinical Research Management Group LLC
    Upland, California 91786, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Sunwise Clinical Research LLC
    Walnut Creek, California 94549, United States
    Recruiting
  • MCB Clinical Research Centers, Inc.
    Colorado Springs, Colorado 80910, United States
    Recruiting
  • Mountain View Clinical Research
    Denver, Colorado 80209, United States
    Recruiting
  • University of Connecticut School of Medicine Psychiatry Department
    Farmington, Connecticut 06030, United States
    Recruiting
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
    Recruiting
  • D&H Pompano Research Center, LLC
    Margate, Florida 33063, United States
    Recruiting
  • Premier Clinical Research Institute, Inc.
    Miami, Florida 33122, United States
    Recruiting
  • Miami Dade Medical Research Institute
    Miami, Florida 33176, United States
    Recruiting
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
    Recruiting
  • CenExel iRS (iResearch Savannah)
    Savannah, Georgia 31405, United States
    Recruiting
  • Revive Research Institute
    Elgin, Illinois 60123, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • KUMC-Wichita
    Wichita, Kansas 66160, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Quantum Research Associates Corp.
    Louisville, Kentucky 40218, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Mayflower Clinical
    Russells Mills, Massachusetts 02747, United States
    Recruiting
  • Vector Clinical Trials
    Las Vegas, Nevada 89128, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Neurobehavioral Research, Inc.
    Cedarhurst, New York 11516, United States
    Recruiting
  • Insight Clinical Trials LLC
    Independence, Ohio 44131, United States
    Recruiting
  • Sooner Clinical Research, Inc.
    Oklahoma City, Oklahoma 73116, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18103, United States
    Recruiting
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Austin Clinical Trial Partners
    Austin, Texas 78737, United States
    Recruiting
  • InSite Clinical Research, LLC
    DeSoto, Texas 75115, United States
    Recruiting
  • Baylor College of Medicine, Psychiatry and Behavioral Sciences
    Houston, Texas 77030, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Clinical Trials of Texas LLC
    San Antonio, Texas 78229, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Grayline Research Center
    Wichita Falls, Texas 76309, United States
    Recruiting
  • Andes Clinical Research
    Orem, Utah 84097, United States
    Recruiting
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
    Withdrawn

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Sep 2027, 31 months after the start.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's planned 31 months is above that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2024
First posted
Aug 9, 2024
StartActual
Feb 3, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2027
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06547489
Lead sponsor
Syndeio Biosciences, Inc
Collaborators
Worldwide Clinical Trials
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Feb 3, 2025
Primary completion
Sep 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 3, 2026

Study contacts

Karen Raudibaugh
Contact
karen.raudibaugh@syndeio.bio
781-786-1545
Kelly Kosko
Contact
kelly.kosko@syndeio.bio
215-510-6405
Aaron Koenig, MD
study chair · Syndeio Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zelquistinel

Start the discussion